For life sciences, hospitals and the patients they treat
For life sciences companies and care providers: evidence for your endpoint, your reimbursement dossier and your launch — collected once, carried across the life of the asset.
Two moments decide how far a therapy travels: whether the trial endpoint holds, and whether the right patients start and stay on treatment. We work on both, with one data architecture underneath.
An outcome measure designed to carry a clinical endpoint keeps collecting after approval. The same instrument supports the market access dossier, then measures real-world persistence. Evidence compounds across the asset, instead of being rebuilt at each step of the lifecycle, for pharmaceutical and device programs alike.
We work with life sciences companies across the life cycle of a product. Clinical teams use our eCOA and patient finding solutions to reach higher endpoint collection adherence and shorter throughput times. Medical and market access teams use us to collect the evidence that underpins reimbursement and market access files. Commercial teams use our patient support programs and remote monitoring to reach quicker adoption and higher adherence.
The same data endpoint serves all three. Evidence collected for the trial is reused in the reimbursement dossier and at launch. It is gathered once, for the asset you are running now and for the next one.
CLINICAL SUCCESS
Your endpoint, carried — outcome assessments for trials where the patient's own report is the result, the recruitment work that fills them, and the registries that keep the evidence running after the trial closes.
THERAPY SUCCESS
Your launch, built — the right patients found, started and kept on therapy, with the real-world evidence that underpins market access and reimbursement.
Companies we work with.
We work in a focused set of therapeutic and disease areas and know them in depth: epilepsy and rare epilepsy, myasthenia gravis, multiple sclerosis, hidradenitis suppurativa. Programs are live in those areas today, and the clinicians treating your patients often know us before you call.
KOL sites, patient apps with active users, and hospital networks. It is how trials fill on time, and how a program gets adopted once it launches.
More than ten years doing this, with the certifications that come with it: GDPR-compliant data processing, information security under ISO 27001, medical device quality management under ISO 13485, good clinical practice, and pharmacovigilance and materiovigilance reporting. Depending on the therapeutic area and the phase, the solution inside a program carries its own medical device certification. Each program states its own device status, for its own market.
4
A new program is built on an existing, working system, configured for the indication and the phase.
5
One data architecture across trial, dossier and market. Evidence is collected once and reused, instead of being rebuilt at each step of the lifecycle.
And behind all five, the same senior team: the people who design your program are the people who deliver it.
The areas we are already engaged in, with running programs, clinical relationships and data behind them.
Indications sit with the work — the insights and case studies name what each program covers. If your area is not on this list, we may still be working in it. Tell us what you are running.
See the insights →See the case studies →Contact us →How programs actually ran, and what we learned. Worth a read if you are shaping something similar — client names appear once each customer has confirmed in writing.
Whether you are designing a trial, building a reimbursement dossier or planning a launch: tell us where your asset is, and we will show you what we would do and what it would take.
